Most Viewed: Last TWO YEARS
  • Review|Open Access

    Function of cancer cell-derived extracellular matrix in tumor progression

    Gao-Feng Xiong , Ren Xu
    Extracellular matrix (ECM) is an essential component of the tumor microenvironment. Cancer development and progression are associated with increased ECM deposition and crosslink. The chemical and physical signals elicited from ECM are necessary for cancer cell proliferation and invasion. It is well recognized that stromal cells are a major source of ECM proteins. However, recent studies showed that cancer cells are also an active and important component in ECM remodeling. Cancer cells deposit a significant amount of collagen, fibronectin, and tenascin C (TNC). Recent studies demonstrate... Read more
    J Cancer Metastasis Treat 2016;2:357-64. | doi:10.20517/2394-4722.2016.08
    Published on: 18 Sep 2016  | Viewed:26397  | Downloaded:862
    +HTML| PDF
  • Review|Open Access

    Targeting Toll-like receptors against cancer

    Bing Du , Qiu-Li Jiang , Joseph Cleveland , Bing-Rong Liu , Dekai Zhang
    The discovery of Toll-like receptors (TLRs) about 20 years ago was a remarkable achievement not only in the field of immunology but also in the field of medicine. The TLRs are a family of pattern recognition receptors which play an important role in immune responses by recognizing pathogen-associated molecular patterns. The TLRs also recognize danger-associated molecular patterns, which are associated with some diseases such as cancer. Recent evidence shows that TLRs are expressed not only in immune cells but also in tumor cells. The TLRs appear to play a role in tumor progression and... Read more
    J Cancer Metastasis Treat 2016;2:463-70. | doi:10.20517/2394-4722.2016.62
    Published on: 29 Dec 2016  | Viewed:15401  | Downloaded:539
    +HTML| PDF
  • Topic: Cancer Stem Cells: Impact on Treatment|Open Access

    Therapeutic strategies for targeting cancer stem cells

    Yu Jeong Kim , Elizabeth L. Siegler , Natnaree Siriwon , Pin Wang
    The therapeutic limitations of conventional chemotherapeutic drugs present a challenge for cancer therapy; these shortcomings are largely attributed to the ability of cancer cells to repopulate and metastasize after initial therapies. Compelling evidence suggests that cancer stem cells (CSCs) have a crucial impact in current shortcomings of cancer therapy because they are largely responsible for tumor initiation, relapse, metastasis, and chemo-resistance. Thus, a better understanding of the properties and mechanisms underlying CSC resistance to treatments is necessary to improve patient... Read more
    J Cancer Metastasis Treat 2016;2:233-42. | doi:10.20517/2394-4722.2016.26
    Published on: 8 Jul 2016  | Viewed:15179  | Downloaded:1169
    +HTML| PDF
  • Topic: Circulating Tumor Cells: Diagnostics and Clinical Applications|Open Access

    Insights into mechanisms of tumor dissemination from circulating tumor cell lines of small cell lung cancer

    Gerhard Hamilton , Barbara Rath
    Despite the fact that the majority of cancer patients succumb to metastatic disease, most aspects of tumor metastasis are not understood in detail at present. Cell biologic steps of dissemination are difficult to characterize in human tumors and research is in large part confined to cell line and experimental animal studies. Epithelial-mesenchymal transition (EMT), intravasation of malignant cells, dissemination as circulating tumor cells (CTCs) and eventually mesenchymal-epithelial transition (MET) at distal sites are steps believed to be involved in metastasis. Small cell lung cancer... Read more
    J Cancer Metastasis Treat 2016;2:446-52. | doi:10.20517/2394-4722.2016.57
    Published on: 16 Dec 2016  | Viewed:14491  | Downloaded:222
    +HTML| PDF
  • Review|Open Access

    The features of peritoneal metastases from gastric cancer

    Gianni Mura , Beatrice Verdelli
    Peritoneal Carcinomatosis (PC) from metastasization of Gastric Cancer (GC), either present at first diagnosis of GC or as recurrence, is considered a fatal disease with no hope of definitive cure. Although newer agents like S1 and docetaxel have shown some promise, the median overall survival with the current first line chemotherapy is only 8 to 14 months, and is not greatly improved by adding targeted therapy. A multi-modal approach with cytoreductive surgery (CRS) associated with hyperthermic intraperitoneal chemotherapy (HIPEC) has been developed along the last two decades in order to... Read more
    J Cancer Metastasis Treat 2016;2:365-74. | doi:10.20517/2394-4722.2016.19
    Published on: 18 Sep 2016  | Viewed:11898  | Downloaded:508
    +HTML| PDF
  • Topic: Cancer Immunotherapy|Open Access

    Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead

    Stanley J. Oiseth , Mohamed S. Aziz
    The knowledge that the body possesses natural defenses to combat cancer existed long before the modern period, with multiple anecdotal reports of tumors miraculously disappearing, sometimes spontaneously or after a febrile or infectious episode. Spontaneous tumor regression of untreated malignant tumors is currently a well-accepted albeit rare phenomenon, and it is recognized that immunosuppression is associated with a higher cancer risk. The treatment of bladder carcinoma by intravesical administration of live attenuated Bacillus Calmette-Guérin bacteria was shown to be very effective in... Read more
    J Cancer Metastasis Treat 2017;3:250-61. | doi:10.20517/2394-4722.2017.41
    Published on: 31 Oct 2017  | Viewed:10824  | Downloaded:1800
    +HTML| PDF
  • Case Report|Open Access

    An unusual case of encapsulated papillary carcinoma of breast

    Kriti Chauhan , Monika Garg
    Intracystic (encapsulated) papillary carcinoma of breast is a rare variant of breast cancer. It is usually a low-grade tumor showing estrogen, progesterone positivity. The authors report an unusual case of intracystic papillary carcinoma showing high nuclear grade, brisk mitosis, and necrosis with triple negativity for estrogen, progesterone, and Her-2/neu receptors, as well as negative axillary lymph nodes. Such cases need to be reported to increase awareness so that they will be managed conservatively, avoiding any overtreatment despite being high grade and triple negative. Read more
    J Cancer Metastasis Treat 2016;2:224-7. | doi:10.20517/2394-4722.2015.63
    Published on: 15 Jun 2016  | Viewed:8871  | Downloaded:207
    +HTML| PDF
  • Topic: Neuroendocrine Tumors|Open Access

    Review of recent advances in medical treatment for neuroendocrine neoplasms: somatostatin analogs and chemotherapy

    Francesca Spada , Monica Valente
    Neuroendocrine neoplasms (NENs) are a heterogeneous group of rare tumours often producing high levels of hormones and causing symptoms. There are a number of different types of NENs. They usually arise as advanced and low/intermediate grade only in a minority of cases, as high grade. Treatment depends on which type and may include surgery, interventional radiology, and systemic treatment, including chemotherapy, somatostatin analogs, interferon α2b, peptide receptor radionuclide therapy, and only for pancreatic neuroendocrine tumors, molecular targeted agents, including everolimus and... Read more
    J Cancer Metastasis Treat 2016;2:313-20. | doi:10.20517/2394-4722.2016.38
    Published on: 31 Aug 2016  | Viewed:7640  | Downloaded:447
    +HTML| PDF
  • Review|Open Access

    Muscarinic receptor signaling and colon cancer progression

    Guofeng Xie , Jean-Pierre Raufman
    Due to the lack of effective treatments, advanced colorectal cancer (CRC) remains a leading cause of cancer death in the United States. Emerging evidence supports the observation that muscarinic receptor (MR) signaling plays a critical role in growth and progression of CRC. MR activation by acetylcholine and bile acids results in transactivation of epidermal growth factor receptors (EGFR) and post-EGFR signal transduction that enhances cell proliferation, migration, and invasion. Here, the authors review recent progress in understanding the molecular mechanisms underlying MR-mediated CRC... Read more
    J Cancer Metastasis Treat 2016;2:195-200. | doi:10.20517/2394-4722.2016.05
    Published on: 15 Jun 2016  | Viewed:6982  | Downloaded:207
    +HTML| PDF
  • Review|Open Access

    DNA damage-induced nuclear factor-kappa B activation and its roles in cancer progression

    Wei Wang , Arul M. Mani , Zhao-Hui Wu
    DNA damage is a vital challenge to cell homeostasis. Cellular responses to DNA damage (DDR) play essential roles in maintaining genomic stability and survival, whose failure could lead to detrimental consequences such as cancer development and aging. Nuclear factor-kappa B (NF-kB) is a family of transcription factors that plays critical roles in cellular stress response. Along with p53, NF-kB modulates transactivation of a large number of genes which participate in various cellular processes involved in DDR. Here the authors summarize the recent progress in understanding DNA damage response... Read more
    J Cancer Metastasis Treat 2017;3:45-59. | doi:10.20517/2394-4722.2017.03
    Published on: 27 Mar 2017  | Viewed:5437  | Downloaded:211
    +HTML| PDF
  • Review|Open Access

    Nanocarrier drugs in the treatment of brain tumors

    Tereza Cerna , Marie Stiborova , Vojtech Adam , Rene Kizek , Tomas Eckschlager
    Nanoparticle-mediated targeted delivery of drugs might significantly reduce the dosage and optimize their release properties, increase specificity and bioavailability, improve shelf life, and reduce toxicity. Some nanodrugs are able to overcome the blood-brain barrier that is an obstacle to treatment of brain tumors. Vessels in tumors have abnormal architecture and are highly permeable; moreover, tumors also have poor lymphatic drainage, allowing for accumulation of macromolecules greater than approximately 40 kDa within the tumor microenvironment. Nanoparticles exploit this feature, known... Read more
    J Cancer Metastasis Treat 2016;2:407-16. | doi:10.20517/2394-4722.2015.95
    Published on: 31 Oct 2016  | Viewed:5098  | Downloaded:395
    +HTML| PDF
  • Review|Open Access

    The role of human papillomaviruses in cancer progression

    Pinar Tulay , Nedime Serakinci
    The importance of human papillomavirus (HPV) infection and its role in the progress of cancer have been widely evaluated. The understanding of HPV association with certain cancers, such as cervical cancer, is very well established. A big step forward in the prevention of HPV associated cancers with the use of early detection by screening strategies has also been taken. In the last decade, development of HPV vaccination has reduced the number of cases in HPV infections and infection induced cancers. In this report, we review the HPV pathogenesis and highlight the mechanism of HPV involvement... Read more
    J Cancer Metastasis Treat 2016;2:201-13. | doi:10.20517/2394-4722.2015.67
    Published on: 15 Jun 2016  | Viewed:4809  | Downloaded:378
    +HTML| PDF
  • Commentary|Open Access

    A new twist to neurotransmitter receptors and cancer

    Hildegard M. Schuller
    J Cancer Metastasis Treat 2017;3:71-7. | doi:10.20517/2394-4722.2017.18
    Published on: 28 Apr 2017  | Viewed:4497  | Downloaded:189
    +HTML| PDF
  • Topic: Circulating Tumor Cells: Diagnostics and Clinical Applications|Open Access

    A versatile method for enumeration and characterization of circulating tumor cells from patients with breast cancer

    Ujjwala M. Warawdekar , Vani Parmar , Aruna Prabhu , Abhay Kulkarni , Meenal Chaudhari , Rajendra A. Badwe
    Aim: To establish a standardized protocol for the isolation and enumeration of circulating tumor cells (CTCs) from peripheral blood of patients with metastatic breast cancer. Methods: The protocol used tumor cells spiked in a lymphoid cell line with detection by flow cytometry and quantitative reverse transcription polymerase chain reaction (QRT-PCR). Cells of the human mammary cancer subtypes were spiked into Jurkat cells, which served as the lymphocyte designate in numbers from 10 to 500 per 105 Jurkat cells. This mixed population was probed for CD45, EpCAM, and pancytokeratin acquired... Read more
    J Cancer Metastasis Treat 2017;3:23-33. | doi:10.20517/2394-4722.2016.66
    Published on: 23 Feb 2017  | Viewed:4431  | Downloaded:151
    +HTML| PDF
  • Original Article|Open Access

    Real-time quantitative PCR array to study drug-induced changes of gene expression in tumor cell lines

    Stefano Amatori , Giuseppe Persico , Mirco Fanelli
    Aim: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) is still the “gold standard” for quantitative analysis of mRNA and the study of differentially expressed genes. Methods: The authors describe a RT-qPCR array that exploits SYBR Green dye-based detection to perform reliable gene expression analysis on 41 genes involved in several pathways linked to DNA damage response, cell cycle progression, cellular senescence, and programmed cell death. To validate the RT-qPCR array, the authors investigated changes of the gene expression profile of HeLa cells treated with two... Read more
    J Cancer Metastasis Treat 2017;3:90-9. | doi:10.20517/2394-4722.2017.22
    Published on: 24 May 2017  | Viewed:4287  | Downloaded:268
    +HTML| PDF
  • Review|Open Access

    Bacteria in cancer therapy: beyond immunostimulation

    Wheeler Torres , Víctor Lameda , Luis Carlos Olivar , Carla Navarro , Jorge Fuenmayor , Adrián Pérez , Andres Mindiola , Milagros Rojas , María Sofía Martínez , Manuel Velasco , Joselyn Rojas , Valmore Bermudez
    Currently, conventional therapies in cancer are improving; chemotherapy, radiotherapy and surgery have increased survival significantly. New therapies have arisen with the same goal; immunotherapy has appeared as a promising option in the fight against cancer stimulating the immune system by inducing innate and adaptive responses. These responses include release of pro-inflammatory cytokines, making the immune system capable to eliminate or protect against multiple tumors. Nowadays, many of these therapies are being used in clinical settings, such as checkpoint inhibitors, monoclonal anti... Read more
    J Cancer Metastasis Treat 2018;4:4. | doi:10.20517/2394-4722.2017.49
    Published on: 24 Jan 2018  | Viewed:4146  | Downloaded:374
    +HTML| PDF
  • Topic: Neuroendocrine Tumors|Open Access

    Medical therapy for advanced gastro-entero-pancreatic and bronchopulmonary neuroendocrine tumors

    Mariangela Torniai , Silvia Rinaldi , Francesca Morgese , Giulia Ricci , Azzurra Onofri , Christian Grohé , Rossana Berardi
    Neuroendocrine tumors (NETs) represent a spectrum of rare neoplasms arising in different organism sites. Depending on the site of onset, they also can be distinguished using lab exams (secreting vs. nonsecreting), clinical symptoms (functioning vs. nonfunctioning), behavioral, morphological characteristics (tumor cells’ architectural growth patterns, mitotic and Ki-67 index, presence of necrosis), and grade of cellular differentiation. The aim of this review is to focus on the main signaling pathways targeted by medical treatments of advanced sporadic gastro-entero-pancreatic (GEP) and... Read more
    J Cancer Metastasis Treat 2016;2:329-40. | doi:10.20517/2394-4722.2016.47
    Published on: 31 Aug 2016  | Viewed:4049  | Downloaded:201
    +HTML| PDF
  • Original Article|Open Access

    Oxidative stress and breast cancer biomarkers: the case of the cytochrome P450 2E1

    Subir Singh , Ramkumar Rajendran , Kengo Kuroda , Emiko Isogai , Marija Krstic-Demonacos , Constantinos Demonacos
    Aim: The aim of the study is to investigate the impact of the cytochrome P450 2E1, which is the most efficient CYP450 family member in generating reactive oxygen species (ROS), on cellular energy metabolism of breast cancer cells and therefore the effects of CYP2E1 on breast carcinogenesis. Methods: The estrogen receptor positive MCF-7 and the triple negative MDA-MB-231 breast cancer cells were used as experimental system to estimate ROS generation in these cells overexpressing CYP2E1 and treated with the glycolytic inhibitors 3-bromopyruvate or 2-deoxyglucose in the presence or absence of... Read more
    J Cancer Metastasis Treat 2016;2:268-76. | doi:10.20517/2394-4722.2016.42
    Published on: 29 Jul 2016  | Viewed:4012  | Downloaded:325
    +HTML| PDF
  • Topic: Neuroendocrine Tumors|Open Access

    Circulating neuroendocrine tumors biomarkers. Why? When? How? Suggestions for clinical practice from guidelines and consensus

    Paola Razzore , Giorgio Arnaldi
    Neuroendocrine neoplasms (NETs) are rare tumors that are increasing in incidence. NETs are characterized by heterogeneous biological behaviour, clinical presentation and course. A sensitive and specific diagnostic and prognostic circulating biomarker useful for all sites, grading and staging of neuroendocrine tumors is still an unmet need. The aim of this article was to review current neuroendocrine and oncologic scientific society guidelines and position statements, and propose recommendations for the most frequent clinical practice queries on circulating neuroendocrine tumors biomarkers.... Read more
    J Cancer Metastasis Treat 2016;2:348-56. | doi:10.20517/2394-4722.2016.39
    Published on: 31 Aug 2016  | Viewed:3784  | Downloaded:398
    +HTML| PDF
  • Original Article|Open Access

    Papaya black seeds have beneficial anticancer effects on PC-3 prostate cancer cells

    Khalid S. Alotaibi , Haiwen Li , Reza Rafi , Rafat A. Siddiqui
    Aim: The study investigated the effect of papaya seeds on prostate cancer (PC) using PC-3 cell line because papaya seeds have effects on the male reproductive system notably decreasing sperm concentration, motility, and viability, leading to azoospermia after short-to-long-term treatment. Methods: The black seeds from yellow (ripe) papaya and white seeds from green (unripe) papaya were harvested and then extracted in water, 80% methanol, and hexane. The cytotoxic effects of seeds extracts were determined using a WST-1 proliferation assay. The amount of total polyphenols was determined using... Read more
    J Cancer Metastasis Treat 2017;3:161-8. | doi:10.20517/2394-4722.2017.33
    Published on: 28 Aug 2017  | Viewed:3653  | Downloaded:190
    +HTML| PDF
  • Topic: How does the prostate cancer microenvironment affect the metastatic process and/or treatment outcome?|Open Access

    Androgen-AR axis in primary and metastatic prostate cancer: chasing steroidogenic enzymes for therapeutic intervention

    Agnese C. Pippione , Donatella Boschi , Klaus Pors , Simonetta Oliaro-Bosso , Marco L. Lolli
    Androgens play an important role in prostate cancer (PCa) development and progression. Although androgen deprivation therapy remains the front-line treatment for advanced prostate cancer, patients eventually relapse with the lethal form of the disease. The prostate tumor microenvironment is characterised by elevated tissue androgens that are capable of activating the androgen receptor (AR). Inhibiting the steroidogenic enzymes that play vital roles in the biosynthesis of testosterone (T) and dihydrotestosterone (DHT) seems to be an attractive strategy for PCa therapies. Emerging data... Read more
    J Cancer Metastasis Treat 2017;3:328-61. | doi:10.20517/2394-4722.2017.44
    Published on: 12 Dec 2017  | Viewed:3424  | Downloaded:90
    +HTML| PDF
  • Topic: Neuroendocrine Tumors|Open Access

    Management of hepatic metastases of well/moderately differentiated neuroendocrine tumors of the digestive tract

    Anna La Salvia , Stefano Partelli , Marco Tampellini , Domenico Tamburrino , Massimo Falconi , Giorgio V. Scagliotti , Maria Pia Brizzi
    In neuroendocrine tumors (NETs), liver metastases (LM) represent the most crucial prognostic factor, irrespective of the primary tumor site. At diagnosis, about 65-95% of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) show hepatic metastasis. Management strategies of LM are heterogeneous and range from systemic therapy to liver-directed procedures. The type of systemic therapy used is dependent on the grade and proliferation of the tumor and includes somatostatin analogues, interferon, m-Tor and tyrosine kinase inhibitors, and chemotherapy. Angiographic liver-directed techniques,... Read more
    J Cancer Metastasis Treat 2016;2:294-303. | doi:10.20517/2394-4722.2016.37
    Published on: 17 Aug 2016  | Viewed:3396  | Downloaded:330
    +HTML| PDF
  • Topic: Cancer Stem Cells: Impact on Treatment|Open Access

    Curcumin sensitizes quiescent leukemic cells to antimitotic drug 5-fluorouracil by inducing proliferative responses in them

    Anagha Gardane , Mariyah Poonawala , Anuradha Vaidya
    Long-term quiescence or dormancy is a fundamental feature of cancer stem cells (CSCs) that are genetically identical to the malignant clone but constitute the only cells with tumor propagation potential within the overall tumor population. These quiescent cells show significant resistance to radiation and antiproliferative chemotherapy due to distinctive properties that seem to be related to their stem cell-like character. Hence, successful anticancer therapy must consist of approaches that can target not only the differentiated cancer cells, but also the CSCs. Using serum-starved KG1a cell... Read more
    J Cancer Metastasis Treat 2016;2:245-52. | doi:10.20517/2394-4722.2016.11
    Published on: 8 Jul 2016  | Viewed:3317  | Downloaded:210
    +HTML| PDF
  • Review|Open Access

    Role of adenosine in tumor progression: focus on A2B receptor as potential therapeutic target

    Claudia Sorrentino , Silvana Morello
    Adenosine receptors are a family of G-coupled receptors which mediate the anti-inflammatory and immune-suppressive effects of adenosine in a damaged tissue. A large number of evidence indicate that the accumulation of adenosine under hypoxic conditions favors tumor progression, helping cancer cells to evade immune responses. Tumor cells and/or lymphoid and myeloid cells can express the adenosine-generating enzyme CD73 and/or A2A receptor, which in turn strongly suppresses an effective T-cell-mediated response, while promotes the activity of suppressive cells such as Treg and myeloid-derived... Read more
    J Cancer Metastasis Treat 2017;3:127-38. | doi:10.20517/2394-4722.2017.29
    Published on: 17 Jul 2017  | Viewed:3257  | Downloaded:381
    +HTML| PDF
  • Topic: How does the prostate cancer microenvironment affect the metastatic process and/or treatment outcome?|Open Access

    Prostate cancer exosomes as modulators of the tumor microenvironment

    Alex P. Shephard , Vincent Yeung , Aled Clayton , Jason P. Webber
    Researchers are currently trying to understand why some men with prostate cancer go on to develop aggressive disease whilst others maintain slow growing tumors. Although endogenous genetic anomalies within the tumor cell are important, the prevailing view is that the tissue microenvironment as a whole is the determinant factor. Many studies have focussed on the role of soluble factors in modulating the nature of the tumor microenvironment. There is however a growing interest in the role of extracellular vesicles, including exosomes, as regulators of disease progression. A variety of... Read more
    J Cancer Metastasis Treat 2017;3:288-301. | doi:10.20517/2394-4722.2017.32
    Published on: 6 Dec 2017  | Viewed:3211  | Downloaded:204
    +HTML| PDF
  • Review|Open Access

    A primer on recent developments in cancer immunotherapy, with a focus on neoantigen vaccines

    Taku A. Tokuyasu , Jian-Dong Huang
    Cancer immunotherapy has now been conclusively shown to be capable of producing durable responses for a substantial number of patients. Adoptive cell transfer and checkpoint blockade therapies in particular both demonstrate that antigen-specific immune responses can be dramatically effective, even in previously refractory late stage disease. Such developments, together with advances in technology, have strongly encouraged revisiting the concept of neoantigen vaccines. Here we introduce basic ideas in the field to allow investigators from diverse backgrounds to understand these developments,... Read more
    This article belongs to the Special Issue Cancer Immunotherapy
    J Cancer Metastasis Treat 2018;4:2. | doi:10.20517/2394-4722.2017.52
    Published on: 18 Jan 2018  | Viewed:3084  | Downloaded:197
    +HTML| PDF
  • Topic: Neuroendocrine Tumors|Open Access

    Merkel cell carcinoma responsive to Etoposide: a case report and brief literature review

    Chiara Ancona , Andrea Caff , Giovanni Manfredi Assanto , Stefano Cordio
    Merkel cell carcinoma (MCC), first described in 1972, is an aggressive primary cutaneous carcinoma able to incorporate both epithelial and neuroendocrine features. MCC mainly appears in individuals in their eighth decade and it is related to a high mortality rate. The etiology of this rare disease is not well-understood but ultraviolet radiation exposure, immune suppression, and aging have a consistent role in its pathogenesis. Usually, clinical lesions appear as asymptomatic coloured dermal nodules. The tumour can involve lymph nodes but further evaluation with imaging is recommended. The... Read more
    J Cancer Metastasis Treat 2016;2:310-2. | doi:10.20517/2394-4722.2016.46
    Published on: 17 Aug 2016  | Viewed:3032  | Downloaded:121
    +HTML| PDF
  • Case Report|Open Access

    Osteonecrosis of the jaw in a patient with acute myeloid leukemia, who received azacitidine

    Ourania Nicolatou-Galitis , Dimitra Galiti , Maria Moschogianni , Sotirios Sachanas , Beatrice J. Edwards , Cesar A. Migliorati , Gerassimos Pangalis
    The first case of osteonecrosis of the jaw (ONJ) related to azacitidine therapy was reported. A 64-year-old male with acute myeloid leukemia, who received 5-azacitidine, presented with pain and purulence of the right second premolar. An unsuccessful endodontic therapy resulted in dental extraction 6 months later. The post-extraction non-healing socket was managed with antibiotics and multiple surgical debridements without response. ONJ stage 2 was diagnosed 12 months after the initial symptoms of pain and purulence and was managed conservatively. Currently the patient is still receiving... Read more
    J Cancer Metastasis Treat 2016;2:220-3. | doi:10.20517/2394-4722.2016.06
    Published on: 15 Jun 2016  | Viewed:2961  | Downloaded:145
    +HTML| PDF
  • Original Article|Open Access

    TGF-β stimulation of EMT programs elicits non-genomic ER-α activity and anti-estrogen resistance in breast cancer cells

    Maozhen Tian , William P. Schiemann
    Aim: Estrogen receptor-α (ER-α) activation drives the progression of luminal breast cancers. Signaling by transforming growth factor-β (TGF-β) typically opposes the actions of ER-α; it also induces epithelial-mesenchymal transition (EMT) programs that promote breast cancer dissemination, stemness and chemoresistance. The impact of EMT programs on nongenomic ER-α signaling remains unknown and was studied herein. Methods: MCF-7 and BT474 cells were stimulated with TGF-β to induce EMT programs, at which point ER-α expression, localization, and nongenomic interactions with receptor tyrosine... Read more
    J Cancer Metastasis Treat 2017;3:150-60. | doi:10.20517/2394-4722.2017.38
    Published on: 21 Aug 2017  | Viewed:2938  | Downloaded:144
    +HTML| PDF
  • Topic: How does the prostate cancer microenvironment affect the metastatic process and/or treatment outcome?|Open Access

    Tumor heterogeneity and therapy resistance - implications for future treatments of prostate cancer

    Fiona M. Frame , Amanda R. Noble , Sandra Klein , Hannah F. Walker , Rakesh Suman , Richard Kasprowicz , Vin M. Mann , Matt S. Simms , Norman J. Maitland
    Aim: To develop new therapies for prostate cancer, disease heterogeneity must be addressed. This includes patient variation, multi-focal disease, cellular heterogeneity, genomic changes and epigenetic modification. This requires more representative models to be used in more innovative ways. Methods: This study used a panel of cell lines and primary prostate epithelial cell cultures derived from patient tissue. Several assays were used; alamar blue, colony forming assays, γH2AX and Ki67 immunofluorescence and comet assays. Ptychographic quantitative phase imaging (QPI), a label-free imaging... Read more
    J Cancer Metastasis Treat 2017;3:302-14. | doi:10.20517/2394-4722.2017.34
    Published on: 6 Dec 2017  | Viewed:2768  | Downloaded:263
    +HTML| PDF
  • Original Article|Open Access

    Sunitinib effectiveness and safety as first line treatment in metastatic renal cell carcinoma, in the Costa Rican population

    Esteban Gonzalez , Silvia Alfaro , Allan Ramos-Esquivel , Denis Ulises Landaverde
    Aim: Tyrosine kinase inhibitors are part of the armamentarium to treat metastatic renal cell carcinomas (mRCC). Costa Rica has approved sunitinib in the first line setting. The authors conducted a retrospective study to address the effectiveness and safety profile of sunitinib in our population in terms of overall survival (OS) and progression free survival (PFS). Methods: The authors analyzed all patients who were treated with sunitinib diagnosed with mRCC in the three National Hospitals (Hospital Mexico, Hospital San Juan de Dios, and Hospital Calderon Guardia) from February 2007 to June... Read more
    J Cancer Metastasis Treat 2016;2:396-401. | doi:10.20517/2394-4722.2016.27
    Published on: 21 Oct 2016  | Viewed:2689  | Downloaded:201
    +HTML| PDF
  • Original Article|Open Access

    Evaluation of anti-metastatic effect of chitosan nanoparticles on esophageal cancer-associated fibroblasts

    Pravin D. Potdar , Aashutosh U. Shetti
    Aim: Esophageal cancer is one of the major types of cancers, causing death of approximately 5% of all cancer deaths. This is due, in large part, to both relatively ineffectual and unavailable treatment. In order to develop an effective treatment strategy against esophageal cancer, it is important to target metastatic genes. In the present study, we have used a cancer-associated fibroblast (CAF) cell line derived from culturing peripheral blood mononuclear cells from a metastatic esophageal cancer patient to see whether chitosan nanoparticles (Ch-Np) treatment can modulate the metastatic... Read more
    J Cancer Metastasis Treat 2016;2:259-67. | doi:10.20517/2394-4722.2016.25
    Published on: 29 Jul 2016  | Viewed:2662  | Downloaded:171
    +HTML| PDF
  • Topic: Circulating Tumor Cells: Diagnostics and Clinical Applications|Open Access

    Profiling of circulating tumor cells in liquid biopsies from metastatic cancer patients

    Pravin D. Potdar , Keerti Sen
    Aim: Circulating tumor cells (CTCs) are crucial to tumor metastasis and valuable for prediction of clinical outcome in patients with solid tumors. Here, the authors aimed to establish a method for enumeration and characterization of CTCs from liquid biopsies. Methods: Peripheral blood mononuclear cells (PBMCs) were separated from blood samples from patients with metastatic cancer using Ficoll-Hypaque gradients and cultured to isolate and enumerate CTCs. Cultured CTCs were morphologically characterized by light and phase contrast microscopy. The tumorigenicity of Ficoll-Hypaque-separated... Read more
    J Cancer Metastasis Treat 2017;3:6-15. | doi:10.20517/2394-4722.2016.53
    Published on: 23 Jan 2017  | Viewed:2468  | Downloaded:204
    +HTML| PDF
  • Topic: Neuroendocrine Tumors|Open Access

    Neuroendocrine tumors: a multidisciplinary approach for a complex disease

    Rossana Berardi
    J Cancer Metastasis Treat 2016;2:277-8. | doi:10.20517/2394-4722.2016.50
    Published on: 17 Aug 2016  | Viewed:2441  | Downloaded:210
    +HTML| PDF
  • Topic: Circulating Tumor Cells: Diagnostics and Clinical Applications|Open Access

    Lung cancer biopsy dislodges tumor cells into circulating blood

    Noriyoshi Sawabata , Tomotaka Kitamura , Yuko Nitta , Tomoyo Taketa , Takeshi Ohno , Tatsuya Fukumori , Takeru Hyakutake , Takahito Nakamura
    Aim: A “seed” of lung cancer metastasis is circulating tumor cells (CTCs), which may be dislodged from a tumor during biopsy. This possibility was assessed among patients who underwent lung tumor biopsy using flexible fiber-topic bronchoscopy (FFB). Methods: The study involved six patients with non-small cell lung cancer who underwent FFB biopsy to diagnose a lesion pathologically (5 males and 1 female, median age 63 years, six adenocarcinomas, of four clinical-stage IA, one stage IB, and one stage IIIA), CTCs were extracted from the peripheral vein blood at pre-FFB and at post-FFB using a... Read more
    J Cancer Metastasis Treat 2017;3:16-20. | doi:10.20517/2394-4722.2016.67
    Published on: 23 Jan 2017  | Viewed:2135  | Downloaded:191
    +HTML| PDF
  • Case Report|Open Access

    EGFR mutation--a commonly neglected mutation in squamous cell lung carcinoma

    Rajeev Saini , Ullas Batra , Akhil Jain , Chaturbhuj Agrawal
    Lung cancer is the leading cause of cancer-related death worldwide. Advances in molecular biology have unveiled various targetable mutations with epidermal growth factor receptor (EGFR) being most common. EGFR testing is recommended for all locally advanced or metastatic adenocarcinoma lungs but recommendation in squamous histology is uncertain. However, just on the basis of histology, EGFR testing should not be withheld in patients diagnosed as squamous cell cancer on small biopsy, in females, never smokers and Asians. We report two cases with squamous cell lung cancer diagnosed on small... Read more
    J Cancer Metastasis Treat 2016;2:253-4. | doi:10.20517/2394-4722.2016.07
    Published on: 20 Jul 2016  | Viewed:2119  | Downloaded:172
    +HTML| PDF
  • Review|Open Access

    Cytogenetic and molecular basis of BCR-ABL myelodysplastic syndrome: diagnosis and prognostic approach

    Mostafa Paridar , Omid Kiani Ghalesardi , Mohammad Seghatoleslami , Ahmad Ahmadzadeh , Abbas Khosravi , Najmaldin Saki
    Myelodysplastic syndromes (MDS) include a heterogeneous group of blood disorders generally afflicting older people. Several genetic factors have been reported from these patients that have an important role in the diagnosis, prognosis, and treatment of this disease. BCR-ABL1 is a genetic factor that has occasionally been reported in some studies. This review attempts to characterize MDS patients reported to harbor this fusion and to assess the diagnostic, therapeutic, and prognostic potential of BCR-ABL1 fusionin MDS patients. This review showed that BCR-ABL fusion has been reported in 22... Read more
    J Cancer Metastasis Treat 2017;3:38-44. | doi:10.20517/2394-4722.2016.61
    Published on: 28 Feb 2017  | Viewed:2092  | Downloaded:189
    +HTML| PDF
  • Review|Open Access

    Using circulating tumor cells to advance precision medicine in prostate cancer

    Giuseppe Galletti , Daniel Worroll , David M. Nanus , Paraskevi Giannakakou
    The field of circulating tumor cell (CTC) enrichment has seen many emerging technologies in recent years, which have resulted in the identification and monitoring of clinically relevant, CTC-based biomarkers that can be analyzed routinely without invasive procedures. Several molecular platforms have been used to investigate the molecular profile of the disease, from high throughput gene expression analyses down to single cell biological dissection. The established presence of CTC heterogeneity nevertheless constitutes a challenge for cell isolation as the several subpopulations can... Read more
    J Cancer Metastasis Treat 2017;3:190-205. | doi:10.20517/2394-4722.2017.45
    Published on: 27 Sep 2017  | Viewed:2048  | Downloaded:142
    +HTML| PDF
  • Case Report|Open Access

    Carcinoma cervix with fat attenuating skull metastases

    Anuradha Kapali , Atmakuri Sateesh Kumar , Mukunda Malathi , S. D. Shamsundar
    Skeletal metastasis in carcinoma cervix occurs in about 0.8-23% of cases. These lesions are usually radiographically lytic. Very few cases of metastases to the skull have been identified, about 5 cases to the best of our knowledge. We present a case of adenosquamous cell carcinoma of cervix with fat attenuating skull metastases in a 38-year-old lady that is not reported till date. The lesion was lytic, expansile and with negative attenuation of -15 to -30 Hounsfield units corresponding to fat.Metastases must be included in the differentials of scalp lesions. A history of recent onset of... Read more
    J Cancer Metastasis Treat 2016;2:228-30. | doi:10.20517/2394-4722.2015.87
    Published on: 15 Jun 2016  | Viewed:2047  | Downloaded:117
    +HTML| PDF
  • Topic: Neuroendocrine Tumors|Open Access

    Neuroendocrine tumors: current therapies, notch signaling, and cancer stem cells

    Judy S. Crabtree , Lucio Miele
    Neuroendocrine tumors (NETs) encompass a broad spectrum of malignancies all derived from neuroendocrine cell lineage, affecting many different organs including the gastrointestinal (GI) tract, the endocrine pancreas, the thyroid, the skin and the respiratory tract. These tumors as a group are very heterogeneous, with varying characteristics attributed to each tissue of origin and tumor subtype. The pathogenesis of the different subtypes of NETs is not fully understood, but recent studies suggest the Notch signaling pathway may be dysregulated in these tumors either by under or... Read more
    J Cancer Metastasis Treat 2016;2:279-93. | doi:10.20517/2394-4722.2016.30
    Published on: 17 Aug 2016  | Viewed:1949  | Downloaded:307
    +HTML| PDF
  • Original Article|Open Access

    Do elderly NSCLC stage IV patients benefit from chemotherapy as well as younger? An analysis from clinical practice date

    Regina Gironés , Pedro López , Rebeca Chulvi , Mamen Cañabate
    Aim: The aim of this study was to evaluate the efficacy of treatment related to age in metastatic non-small cell lung cancer (NSCLC). We compared young and elders (> 70) in the setting of a regional Spanish hospital. We hypothesized that elder benefit as much as younger patients from chemotherapy in stage IV NSCLC. The study was limited to performance status 0-2. Methods: Clinical and demographic characteristics were reviewed form medical records. Type of treatment was collected and compared, as well as benefit from treatment, in terms of overall survival. Results: 322 patients (162... Read more
    J Cancer Metastasis Treat 2016;2:379-87. | doi:10.20517/2394-4722.2016.20
    Published on: 30 Sep 2016  | Viewed:1949  | Downloaded:125
    +HTML| PDF
  • Case Report|Open Access

    Isolated breast metastasis mimicking as second primary cancer - a case report

    Manjari Shah , Umang Mithal , Sandeep Agarwal , Sweety Gupta , Disha Tiwari , Shashank Srinivasan , Asheesh Jain , Ritu Chandra
    Primary carcinoma of breast is common but breast is a rare site of metastasis and metastases from extramammary sites are even rarer. Metastasis to breast from rectal carcinoma is very unusual and till now 19 cases of breast secondaries from colorectal carcinoma have been reported in literature which include 14 cases where the primary site was colon and remaining 5 were from the rectum. Here the authors report a case of adenocarcinoma anorectum who had completed treatment and after 4 months developed a lump in her left breast which was metastatic. Metastatic lesions of breast are usually... Read more
    J Cancer Metastasis Treat 2016;2:391-5. | doi:10.20517/2394-4722.2016.22
    Published on: 30 Sep 2016  | Viewed:1943  | Downloaded:124
    +HTML| PDF
  • Topic: Circulating Tumor Cells: Diagnostics and Clinical Applications|Open Access

    Circulating tumor cells: hope to diagnose and treat metastatic cancer

    Pravin D. Potdar
    J Cancer Metastasis Treat 2017;3:1-5. | doi:10.20517/2394-4722.2016.72
    Published on: 12 Jan 2017  | Viewed:1845  | Downloaded:145
    +HTML| PDF
  • Topic: Neuroendocrine Tumors|Open Access

    Orbital lesions, an exceedingly rare site of neuroendocrine tumor metastasis

    Sara Pusceddu , Massimo Milione , Silvia Ortolani , Alessio Pellegrinelli , Marco Brugia , Filippo de Braud , Lorenzo Antonuzzo
    Neuroendocrine tumors are rare neoplasms arising primarily in the gastrointestinal tract and lung. The liver is the most common site of metastases, but these tumors can rarely metastasize to atypical sites. Surgery is the only curative approach while the optimal medical treatment is debated. From this perspective, a multidisciplinary approach for each single case becomes very important. In this report we describe the case of a male affected by a single intraorbital metastasis from a midgut well differentiated neuroendocrine tumor. The patient refused surgical removal and therefore he was at... Read more
    J Cancer Metastasis Treat 2016;2:341-4. | doi:10.20517/2394-4722.2016.41
    Published on: 31 Aug 2016  | Viewed:1812  | Downloaded:145
    +HTML| PDF
  • Case Report|Open Access

    Malignant eccrine acrospiroma with nodal and bone metastasis

    Burhan Wani , Shiekh Aejaz Aziz , Mohmad Hussain Mir , Gull Mohammad Bhat , Abdul Rashid Lone
    Acrospiromas are cutaneous tumors of sweat duct differentiation. Although various eccrine sweat gland tumours including benign acrospiroma are widely reviewed, malignant acrospiroma is rarely reported. Clinically, they resemble other cutaneous lesions and the primary treatment is wide local excision with or without lymph node dissection. The efficacy of adjuvant chemotherapy and radiation therapy requires further investigation. Read more
    J Cancer Metastasis Treat 2016;2:255-8. | doi:10.20517/2394-4722.2015.92
    Published on: 20 Jul 2016  | Viewed:1793  | Downloaded:98
    +HTML| PDF
  • Short Communication|Open Access

    Management of choroidal metastasis using external beam radiotherapy: a retrospective study and review of the literature

    Zakaria Ahmed Youbi , Enachescu Ciprian , Caraivan Ionela , Bennani Zineb , Khounigere Majdouline , Kotzki Léa , Pialat Pierre-Marie , Sesques Pierre , Yossi Séna
    Aim: Choroidal metastases are rare in the evolution of solid cancers and constitute exceptional metastatic sites involving functional visual prognosis. The authors conducted a retrospective study to determine the interest of external radiotherapy for the treatment of choroidal metastases. Methods: The authors reviewed the records of 28 patients with choroidal metastases who had breast (n = 15), lung (n = 9), ovarian (n = 1), kidney (n = 1), prostate (n = 1) cancer or carcinoma with unknown primitive at the moment of the diagnosis (n = 1). The median age was 58 years (extremes: 34-71 years).... Read more
    J Cancer Metastasis Treat 2017;3:105-10. | doi:10.20517/2394-4722.2017.07
    Published on: 30 Jun 2017  | Viewed:1724  | Downloaded:143
    +HTML| PDF
  • Minireview|Open Access

    Treatment of liver metastases in patients selected for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis

    Antonio Sommariva
    Cytoreductive surgery (CS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have gained increasing consensus in treatment of peritoneal carcinomatosis from colorectal cancer. The presence of liver metastases is generally considered a contraindication for CS + HIPEC, as hepatic involvement no longer represents a loco-regional aspect of disease. Despite this, liver resection (LR) has been tested in selected cases in combination with CS + HIPEC for treatment of peritoneal carcinomatosis with liver metastasis. Relevant studies on this topic were identified through a search in the... Read more
    J Cancer Metastasis Treat 2017;3:362-7. | doi:10.20517/2394-4722.2017.37
    Published on: 21 Dec 2017  | Viewed:1650  | Downloaded:58
    +HTML| PDF
  • Original Article|Open Access

    Combination of insulin-like growth factor-1, IGF binding protein-3, chromogranin A and prostate specific antigen can improve the detection of prostate cancer

    Saleh Ahmed Kamaleldin Saleh , Heba Mohamed Adly , Anmar Mohammed Nassir
    Aim: Prostate cancer (PCa) is the second most prevalent male cancer worldwide and designated the sixth most frequent male cancer in Arab countries. Although prostate specific antigen (PSA) has become the best and most valuable biomarker for screening of PCa, elevated levels of PSA can reflect the presence of malignant cells but can overlap with benign prostatic diseases. There is a necessity to develop and improve current tools for early detection and diagnosis of PCa. This study was done to evaluate the validation of serum insulin-like growth factor-1 (IGF-1), IGF binding protein-3... Read more
    J Cancer Metastasis Treat 2017;3:82-9. | doi:10.20517/2394-4722.2017.20
    Published on: 24 May 2017  | Viewed:1641  | Downloaded:93
    +HTML| PDF
  • Case Report|Open Access

    Alkaline phosphatase flare with hyperostosis of bone metastases in lung adenocarcinoma treated with gefitinib

    Hiroto Kaneko , Kazuho Shimura , Yosuke Matsumoto , Mihoko Yoshida , Masafumi Taniwaki , Junya Kuroda
    Alkaline phosphatase (ALP) flare has been reported to occur during cancer treatment as a favorable event, particularly in the presence of bone metastasis. There have been only a few reports in lung cancer and associated radiographic findings have seldom been described. The authors observed ALP flare in a female patient with lung adenocarcinoma soon after the initiation of gefitinib. Moreover, on computed tomography, metastatic lesions of the rib and thoracic spine showed marked hyperostosis, with sizes larger than the original bone structure, suggesting efficacy of gefitinib. The... Read more
    J Cancer Metastasis Treat 2017;3:34-7. | doi:10.20517/2394-4722.2016.70
    Published on: 23 Feb 2017  | Viewed:1619  | Downloaded:100
    +HTML| PDF
  • Topic: Cancer Immunotherapy|Open Access

    Systemic humoral responses of non-muscle-invasive bladder cancer during BCG treatment: less is more

    Fernando M. Calais da Silva , Paula A. Videira , Dário Ligeiro , Maria Guadalupe Cabral , Richard Sylvester , Fernando E. Calais da Silva , Hélder Trindade
    Aim: Intravesical Bacille Calmette-Guérin (BCG) is the mainstay adjuvant treatment of non-muscle-invasive bladder cancer. However, one third of the patients on BCG regimen relapse within the first year of treatment. This study aimed at identifying biomarkers to predict response to BCG treatment. Methods: Gene expression was analyzed in blood cells of 58 patients treated with BCG through six consecutive weekly instillations and then at month 3, 6, 9, and 12. Cytokines tumor necrosis factor (TNF)-α, interleukin (IL)-10, interferon (IFN)-γ, IL-1β, IL-2, IL-4, and IL-6; chemokines CCL2, CCL3,... Read more
    J Cancer Metastasis Treat 2017;3:116-26. | doi:10.20517/2394-4722.2017.25
    Published on: 14 Jul 2017  | Viewed:1615  | Downloaded:95
    +HTML| PDF
  • Topic: Neuroendocrine Tumors|Open Access

    Controversies in the treatment of digestive neuroendocrine tumors

    Maria Rinzivillo , Francesco Panzuto , Gianfranco Delle Fave
    Gastroenteropancreatic neuroendocrine tumors (NETs) have an incidence of 2.39 per 100,000 inhabitants per year, and a prevalence of 35 cases per 100,000 inhabitants; the gap between these rates is due to the relatively long survival time of these tumors, which can be thus considered as chronic oncological diseases. Recently, more therapeutic options have become available, but criteria for defining timing, priority and sequence of different therapeutic options are still debated. This review offers an overview of pancreatic and small bowel NETs, critically underlining the issues that still... Read more
    J Cancer Metastasis Treat 2016;2:304-9. | doi:10.20517/2394-4722.2016.40
    Published on: 17 Aug 2016  | Viewed:1608  | Downloaded:162
    +HTML| PDF
  • Case Report|Open Access

    Metastatic clostridial myonecrosis secondary to perforated metastatic bowel cancer

    Nasser Mohammed Amer , John Karayanis
    Spontaneous metastatic clostridial myonecrosis is a rare condition caused by Clostridium septicum. The underlying lesion is usually either a colonic neoplasm or leukemia. The authors reported a 67-year-old female who presented with acute abdomen secondary to a perforated sigmoid cancer and who developed gas gangrene in her right leg. Unfortunately, despite all resuscitative measures, she died. The authors reviewed the literature; the diagnosis of metastatic myonecrosis was based on a high index of suspicion, development of bullae containing gram-positive rods, and subcutaneous crepitus... Read more
    J Cancer Metastasis Treat 2016;2:402-6. | doi:10.20517/2394-4722.2016.16
    Published on: 21 Oct 2016  | Viewed:1604  | Downloaded:113
    +HTML| PDF
  • Review|Open Access

    Gastric cancer: prevention and treatment of peritoneal metastases

    Paul H. Sugarbaker
    Gastric cancer is an aggressive malignancy that may metastasize through the bloodstream to the liver, through lymphatics to regional lymph nodes, or by penetration of the peritoneal lining of the stomach to result in seeding of the abdominal and pelvis surfaces. Peritoneal metastases are the most common mode of cancer dissemination. Technologies to prevent or treat peritoneal metastases from advanced gastric cancer are presented in this manuscript. The world’s literature, both recent and over the past three decades, was reviewed in order to identify publications that present information... Read more
    This article belongs to the Special Issue Reviews of Gastric Cancer Metastasis and Treatment
    J Cancer Metastasis Treat 2018;4:7. | doi:10.20517/2394-4722.2017.67
    Published on: 9 Feb 2018  | Viewed:1602  | Downloaded:108
    +HTML| PDF
  • Original Article|Open Access

    Impact of health care insurance on overall survival of patients with multiple myeloma and monoclonal gammopathy of undetermined significance

    Srinivas S. Devarakonda , Runhua Shi , Ellen Friday , Reinhold Munker , Jonathan Glass , Francesco Turturro
    Aim: Health care insurance improves access to care and thus outcome in patients with solid tumors. Little information on the impact of health care insurance on hematological malignancies including multiple myeloma exists. The authors aimed to analyze the effect of health care insurance on the survival of patients with multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS) at Louisiana State University Health Sciences Center in Shreveport, LA. Methods: Two hundred fifty seven patients were reviewed, of which 208 had MM and 49 had MGUS. Results: One hundred and... Read more
    J Cancer Metastasis Treat 2017;3:100-4. | doi:10.20517/2394-4722.2017.19
    Published on: 9 Jun 2017  | Viewed:1594  | Downloaded:84
    +HTML| PDF
  • Case Report|Open Access

    Uterine large cell neuroendocrine carcinoma with unusual colonic metastasis

    Antonio Ieni , Giuseppe Angelico , Rosalba De Sarro , Francesco Fleres , Antonio Macrì , Giovanni Tuccari
    A 78-year-old female patient arrived at our practice complaining of progressive abdominal increase and presenting a clinical picture of intestinal obstruction. At physical examination, the abdomen appeared distended, moderately painful with the presence of a mass of hard consistency. Abdominal computed tomography scan showed a large hypodense pelvic mass that indicated a compression and lateral deviation of the uterus and bladder. Microscopically, the mass showed a uniform solid pattern, composed of medium and large-sized cells with hyperchromatic and pleomorphic nuclei demonstrating high... Read more
    J Cancer Metastasis Treat 2017;3:144-9. | doi:10.20517/2394-4722.2017.15
    Published on: 16 Aug 2017  | Viewed:1586  | Downloaded:77
    +HTML| PDF
  • Review|Open Access

    Current challenges and opportunities in treating hypoxic prostate tumors

    Declan J. McKenna , Rachel Errington , Klaus Pors
    Hypoxia is a well-established characteristic of prostate tumors and is now recognised as a major contributory factor to both tumor progression and increased resistance to therapy. One strategy to target hypoxic tumor cells is the development of hypoxia-activated prodrugs (HAPs), which are activated in low oxygen environments. Several HAPs have been developed but despite encouraging results from preclinical studies many of these have performed disappointingly in clinical trials. In the developing era of precision medicine, it is clear that more strategic deployment of these agents is... Read more
    This article belongs to the Special Issue How does the prostate cancer microenvironment affect the metastatic process and/or treatment outcome?
    J Cancer Metastasis Treat 2018;4:11. | doi:10.20517/2394-4722.2017.54
    Published on: 1 Mar 2018  | Viewed:1571  | Downloaded:155
    +HTML| PDF
  • Topic: How does the prostate cancer microenvironment affect the metastatic process and/or treatment outcome?|Open Access

    Membrane-type matrix metalloproteinases: expression, roles in metastatic prostate cancer progression and opportunities for drug targeting

    Robert A. Falconer , Paul M. Loadman
    The membrane-type matrix metalloproteinases (MT-MMPs), an important subgroup of the wider MMP family, demonstrate widespread expression in multiple tumor types, and play key roles in cancer growth, migration, invasion and metastasis. Despite a large body of published research, relatively little information exists regarding evidence for MT-MMP expression and function in metastatic prostate cancer. This review provides an appraisal of the literature describing gene and protein expression in prostate cancer cells and clinical tissue, summarises the evidence for roles in prostate cancer... Read more
    J Cancer Metastasis Treat 2017;3:315-27. | doi:10.20517/2394-4722.2017.40
    Published on: 12 Dec 2017  | Viewed:1556  | Downloaded:95
    +HTML| PDF
  • Topic: Neuroendocrine Tumors|Open Access

    Pancreatic neuroendocrine tumor with hypoglycemia and elevated insulin-like growth factor II: a case report

    Roberta Modica , Antonella Di Sarno , Annamaria Colao , Antongiulio Faggiano
    Pancreatic neuroendocrine tumors (pNETs) can be associated with different clinical syndromes. Insulinoma is the most common functioning pNET characterized by hypoglycemia and hyperinsulinemia. The authors report a case of a man presenting with hypoglycemia and biochemical features of insulinoma. A pancreatic lesion was found and growth hormone (GH) deficiency was also diagnosed associated with an empty sella present on the pituitary magnetic resonance imaging. The disappearance of hypoglycemia and normalization of GH secretion after surgical resection of the pancreatic lesion, revealed a... Read more
    J Cancer Metastasis Treat 2016;2:345-7. | doi:10.20517/2394-4722.2016.44
    Published on: 31 Aug 2016  | Viewed:1538  | Downloaded:161
    +HTML| PDF
  • Original Article|Open Access

    ERCC1 expression in patients with colorectal cancer: a pilot study

    Kinjal K. Gajjar , Deep Kumari Yadav , Toral P. Kobawala , Trupti I. Trivedi , Hemangini H. Vora , Nandita R. Ghosh
    Aim: Excision repair cross complementation group 1 (ERCC1) has a key role in enhanced DNA damage repair caused by oxaliplatin-based therapy and may lead to resistance of these platinum drugs in colorectal cancer (CRC) patients. Hence, the present preliminary study aimed to explore the role of ERCC1 C/T polymorphism at codon 118 as well as its immunoreactivity in patients with primary CRC. Methods: ERCC1 polymorphism was studied using PCR-RFLP and ERCC1 protein expression was examined by immunohistochemistry in 50 CRC patients. Results: ERCC1 codon 118 C/T polymorphism analysis reported the... Read more
    J Cancer Metastasis Treat 2016;2:471-6. | doi:10.20517/2394-4722.2016.52
    Published on: 29 Dec 2016  | Viewed:1476  | Downloaded:150
    +HTML| PDF
  • Topic: Cancer Immunotherapy|Open Access

    Immunological aspect of the liver and metastatic uveal melanoma

    Mizue Terai , Michael J. Mastrangleo , Takami Sato
    Uveal (eye) melanoma is the most common primary eye malignancy in adults. Despite optimal treatments for primary uveal melanoma, up to 50% of patients subsequently develop systemic metastasis, often in the liver. Once hepatic metastasis develops, the survival of patients is generally short and currently available treatments fail to show meaningful improvement of survival. Recent development of immune checkpoint blockades revolutionized immunotherapy for metastatic cutaneous (skin) melanoma. Unfortunately, metastatic uveal melanoma is unresponsive to this approach, thus there is an unmet... Read more
    J Cancer Metastasis Treat 2017;3:231-43. | doi:10.20517/2394-4722.2017.39
    Published on: 31 Oct 2017  | Viewed:1475  | Downloaded:105
    +HTML| PDF
  • Topic: Cancer Immunotherapy|Open Access

    Cancer immunity and therapy using hyperthermia with immunotherapy, radiotherapy, chemotherapy, and surgery

    Yohsuke Yagawa , Keishi Tanigawa , Yasunobu Kobayashi , Masakazu Yamamoto
    Hyperthermia is a type of medical modality for cancer treatment using the biological effect of artificially induced heat. Even though the intrinsic effects of elevated body temperature in cancer tissues are poorly understood, increasing the temperature of the body has been recognized as a popular therapeutic method for tumorous lesions as well as infectious diseases since ancient times. Recently accumulated evidence has shown that hyperthermia amplifies immune responses in the body against cancer while decreasing the immune suppression and immune escape of cancer. It also shows that... Read more
    J Cancer Metastasis Treat 2017;3:218-30. | doi:10.20517/2394-4722.2017.35
    Published on: 31 Oct 2017  | Viewed:1441  | Downloaded:170
    +HTML| PDF
  • Case Report|Open Access

    A small solitary fibrous tumor of the bladder

    Guido Petracco , Carlo Patriarca
    The authors present a case of histologically benign and incidentally discovered millimetric solitary fibrous tumor of the bladder, invisible to radiologic imaging and clinically benign. The case came to our attention because of repeated episodes of renal colic. As opposed to the present case, solitary fibrous tumor are generally discovered when they reach certain dimensions, being slow-growing, painless masses. Such a tumor of the bladder is a very rare finding, with less than 20 cases reported, and it has yet to be described with such a small size. The main differential diagnoses are... Read more
    J Cancer Metastasis Treat 2016;2:388-90. | doi:10.20517/2394-4722.2016.21
    Published on: 30 Sep 2016  | Viewed:1370  | Downloaded:105
    +HTML| PDF
  • Case Report|Open Access

    Large chest wall fibromatosis with challenging treatment plan

    Rashi Agrawal , Prekshi Choudhary , Arun Kumar Goel , Vaishali Zamre , Sandeep Agarwal , Dinesh Singh
    The primary mode of treatment for desmoid tumors is surgical excision. However, high recurrence rates (39-79%) have been reported when surgery is used alone. The role of adjuvant radiotherapy after surgical resection of primary disease is controversial and should be based on a balanced discussion of potential morbidity from radiotherapy and local recurrence. In this patient, the maximum dimension of tumor was 21 cm. This is a larger chest wall fibromatosis than has been reported thus far, to the best of our knowledge. In this case, post-operative margins were free, but in view of the large... Read more
    J Cancer Metastasis Treat 2017;3:139-43. | doi:10.20517/2394-4722.2017.02
    Published on: 21 Jul 2017  | Viewed:1365  | Downloaded:119
    +HTML| PDF
  • Case Report|Open Access

    Pediatric gliomatosis cerebri presenting with intratumoral hemorrhage leading to poor outcome

    Hiromasa Adachi , Masashi Kitagawa , Toshinari Kawasaki , Takafumi Wataya
    Gliomatosis cerebri (GC) is an uncommon disease, defined as diffuse infiltration of neoplastic glial cells involving at least three cerebral lobes. GCs in young population are rare. We described a case of 14-year-old woman with GC who did not receive any recommended treatment, because the patient’s family refused. The patient had a rapid deterioration in 5 months after first symptoms due to intratumoral bleeding. This is the first case report of intratumoral bleeding after diagnosis of GC is made, resulting in poor outcome. GC may acquire possibility of intratumoral hemorrhage through its... Read more
    J Cancer Metastasis Treat 2016;2:375-8. | doi:10.20517/2394-4722.2016.33
    Published on: 18 Sep 2016  | Viewed:1312  | Downloaded:116
    +HTML| PDF
  • Original Article|Open Access

    Malignant field expression signatures in biopsy samples at diagnosis predict the likelihood of lethal disease in patients with localized prostate cancer

    Gennadi V. Glinsky
    Aim: Overtreatment of early-stage low-risk prostate cancer patients represents a significant problem in disease management and has significant socio-economic implications. Changes in prostate cancer screening and treatment practices in the United States have been associated with the recent decline in overall incidence and concomitant significant increase of the annual incidence of metastatic prostate cancer has been documented. Therefore, development of genetic and molecular markers of clinically significant disease in patients diagnosed with low grade localized prostate cancer would have a... Read more
    J Cancer Metastasis Treat 2017;3:177-89. | doi:10.20517/2394-4722.2017.43
    Published on: 21 Sep 2017  | Viewed:1286  | Downloaded:21
    +HTML| PDF
  • Original Article|Open Access

    Nibrin expression in oral squamous cell carcinoma: association with clinicopathological parameters

    Jigna H. Dave , Hemangini H. Vora , Trupti I. Trivedi , Nandita R. Ghosh
    Aim: The present study sought to discover the role of Nibrin protein in 100 patients with oral squamous cell carcinoma (OSCC) and its potential relationship with clinicopathological parameters. Methods: Nibrin expression was evaluated immunohistochemically using the modified H-score method. Results: The present study included 20% of patients with stage I disease, 22% of patients with stage II disease, 18% of patients with stage III disease, and 40% of patients with stage IV disease. Nibrin showed a significant positive correlation with moderately/poorly differentiated tumor tissues (P =... Read more
    J Cancer Metastasis Treat 2016;2:436-42. | doi:10.20517/2394-4722.2015.82
    Published on: 25 Nov 2016  | Viewed:1286  | Downloaded:140
    +HTML| PDF
  • Original Article|Open Access

    The synergy of Helicobacter pylori and lipid metabolic disorders in induction of Th17-related cytokines in human gastric cancer

    Jie Liu , Han Wang , Gang Chen , Mo Yang , Zhi-Xian Wu , Russell Erick Ericksen , Alice Sze Tsai Wong , Weiping Han , Jin-Zhang Zeng
    Aim: To study the impact of Helicobacter pylori (H. pylori) and lipid metabolic disorder on the expression of Th17-related cytokines in gastric cancer (GC). Methods: GC specimens were randomly collected from 42 patients, of whom 15 had H. pylori infection and 27 were without. Tumor RNA was extracted for reverse transcription quantitative polymerase chain reaction quantification of gene expression. Results: The mRNA levels of interleukin (IL)-6 and leptin, which are known to regulate Th17 differentiation, were upregulated by 20 and 6 folds, respectively, in H. pylori-infected compared to... Read more
    J Cancer Metastasis Treat 2017;3:169-76. | doi:10.20517/2394-4722.2017.46
    Published on: 29 Aug 2017  | Viewed:1270  | Downloaded:96
    +HTML| PDF
  • Case Report|Open Access

    Pancreatic neuroendocrine tumor liver metastasis in a patient with previously diagnosed pancreatic adenocarcinoma: an unexpected diagnosis

    Mário Fontes-Sousa , Helena Magalhães , Bianca Machado , Olga Sousa , Manuela Machado
    Locally advanced pancreatic carcinoma has an usually poor prognosis despite multimodal approaches and sequential chemotherapy. The authors present a case of a long-term survivor with stage III pancreatic adenocarcinoma achieving partial response after a multimodal approach including local and systemic treatments. However, three years after diagnosis and amidst several episodes of cholangitis, hepatic metastasis were suspected. Despite pancreatic adenocarcinoma being the obvious culprit for metastization, a hepatic biopsy was considered at that time given a stable primary disease and... Read more
    J Cancer Metastasis Treat 2018;4:5. | doi:10.20517/2394-4722.2017.70
    Published on: 24 Jan 2018  | Viewed:1267  | Downloaded:57
    +HTML| PDF
  • Original Article|Open Access

    Impact of previous anti-angiogenesis treatment in nivolumab-treated advanced non-small cell lung cancer

    Takefumi Komiya , Chao H. Huang , Prakash Neupane , Stephen K. Williamson , Prabhakar Chalise
    Aim: To investigate how previous systemic therapy such as anti-angiogenesis can influence cancer immunotherapy for non-small cell lung cancer (NSCLC). Methods: A total of 134 patients with advanced NSCLC who were treated with nivolumab were retrospectively reviewed. Correlation between status of prior anti-angiogenesis treatment and clinical characteristics were determined. Impact of prior anti-angiogenesis on therapeutic outcome of nivolumab was investigated for tumor efficacy such as progression-free survival (PFS). Results: Sixteen patients were treated with at least one... Read more
    J Cancer Metastasis Treat 2018;4:1. | doi:10.20517/2394-4722.2017.65
    Published on: 17 Jan 2018  | Viewed:1252  | Downloaded:66
    +HTML| PDF
  • Case Report|Open Access

    Chest wall metastasis in squamous cell carcinoma of buccal mucosa

    Jayesh Shyamnandan Singh , Ashutosh Das Sharma
    Metastases from head and neck cancers is rare occurrence. The common form of failure/recurrence in these cancers are local site recurrence or nodal metastases. Distant metastases are very rare and are most commonly seen in the lung, brain, liver and bones, and the latent period between the development of the primary and the distant metastases is usually long. There are very few cases reported of chest wall metastases from squamous cell carcinoma of head and neck. This article reports such a case of squamous cell carcinoma of buccal mucosa metastasizing to the chest wall four months after... Read more
    J Cancer Metastasis Treat 2017;3:78-81. | doi:10.20517/2394-4722.2017.08
    Published on: 28 Apr 2017  | Viewed:1250  | Downloaded:89
    +HTML| PDF
  • Original Article|Open Access

    Expression of PANDA, LincRNA-p21, PUMA in lung tissues of lung cancer patients in the Xuanwei and non-Xuanwei areas of Yunnan Province

    Kai-Yun Yang , Zhi-Qiang Shen , Yue-Feng He , Kushal Rizal , Hui Tan , An-Ning Chen , Yun-Chao Huang , Guang-Qiang Zhao , Yu-Jie Lei
    Aim: To study the expression of PANDA, LincRNA-p21, and PUMA in lung tissue of patients with lung cancer from Xuanwei of Yunnan Province. Methods: Forty-five cases of lung cancer patients from Xuanwei and 42 lung cancer cases from non-Xuanwei were enrolled. Extraction of RNA was done using the Trizol kit. Real-time fluorescence quantitative PCR assay was done to obtain the relative expression. Results: Expressions of PANDA, LincRNA-p21, and PUMA in male and female patients or in squamous cell carcinoma and adenocarcinoma were not significantly different (P > 0.05). However, expression of... Read more
    J Cancer Metastasis Treat 2017;3:65-70. | doi:10.20517/2394-4722.2016.65
    Published on: 27 Mar 2017  | Viewed:1243  | Downloaded:113
    +HTML| PDF
  • Meeting Abstracts|Open Access

    Obergurgl Research Conference Abstracts on "Cancer Stem Cells: Impact on Treatment"

    Ira-Ida Skvortsova
    J Cancer Metastasis Treat 2016;2:417-35. | doi:10.20517/2394-4722.2016.58
    Published on: 16 Nov 2016  | Viewed:1190  | Downloaded:138
    +HTML| PDF
  • Topic: How does the prostate cancer microenvironment affect the metastatic process and/or treatment outcome?|Open Access

    HOX transcription factors and the prostate tumor microenvironment

    Richard Morgan , Hardev S. Pandha
    It is now well established that the tumor microenvironment plays an essential role in the survival, growth, invasion, and spread of cancer through the regulation of angiogenesis and localized immune responses. This review examines the role of the HOX genes, which encode a family of homeodomain-containing transcription factors, in the interaction between prostate tumors and their microenvironment. Previous studies have established that HOX genes have an important function in prostate cancer cell survival in vitro and in vivo, but there is also evidence that HOX proteins regulate the... Read more
    J Cancer Metastasis Treat 2017;3:278-87. | doi:10.20517/2394-4722.2017.31
    Published on: 6 Dec 2017  | Viewed:1179  | Downloaded:69
    +HTML| PDF
  • Letter to Editor|Open Access

    Use of a dedicated day care unit in a modern radiation oncology facility -- a short audit

    Tejinder Kataria , Susovan Banerjee , Nimesh Dahima , Deepak Gupta , Trinanjan Basu , Shikha Goyal
    J Cancer Metastasis Treat 2017;3:21-2. | doi:10.20517/2394-4722.2016.73
    Published on: 23 Jan 2017  | Viewed:1175  | Downloaded:107
    +HTML| PDF
  • Review|Open Access

    Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives

    Francesca Battaglin , Alberto Puccini , Madiha Naseem , Marta Schirripa , Martin D. Berger , Ryuma Tokunaga , Michelle McSkane , Taline Khoukaz , Shivani Soni , Wu Zhang , Heinz-Josef Lenz
    The treatment scenario of colorectal cancer (CRC) has been evolving in recent years with the introduction of novel targeted agents and new therapeutic strategies for the metastatic disease. An extensive effort has been directed to the identification of predictive biomarkers to aid patients selection and guide therapeutic choices. Pharmacogenomics represents an irreplaceable tool to individualize patients treatment based on germline and tumor acquired somatic genetic variations able to predict drugs response and risk of toxicities. The growing knowledge of CRC molecular characteristics and... Read more
    This article belongs to the Special Issue Cancer Pharmacogenomics
    J Cancer Metastasis Treat 2018;4:12. | doi:10.20517/2394-4722.2018.04
    Published on: 7 Mar 2018  | Viewed:1157  | Downloaded:118
    +HTML| PDF
  • Case Report|Open Access

    Squamous cell carcinoma of tongue 18 years after renal transplantation: a case report

    Jyoti Poddar , Ashutosh Das Sharma , Ubrangala Suryanarayana Kunikullaya
    Solid organ transplant recipients are at increased risk of developing malignancies, even decades after transplant, due to the prolonged use of immunosuppressant drugs. A 35-year-old male underwent renal transplant for end stage renal disease 18 years previously and was on immunosuppressive drugs since that time and was on regular follow up. In 2016, he developed a squamous cell carcinoma of tongue, which was operated and adjuvant radiation therapy was given. The patient is currently on follow up and asymptomatic. Though squamous cell carcinoma of tongue is a relatively common malignancy in... Read more
    J Cancer Metastasis Treat 2016;2:443-5. | doi:10.20517/2394-4722.2016.36
    Published on: 25 Nov 2016  | Viewed:1125  | Downloaded:115
    +HTML| PDF
  • Topic: Cancer Stem Cells: Impact on Treatment|Open Access

    Introduction to the Special Issue “Cancer Stem Cells: Impact on Treatment”

    Ira-Ida Skvortsova
    J Cancer Metastasis Treat 2016;2:231-2. | doi:10.20517/2394-4722.2016.35
    Published on: 8 Jul 2016  | Viewed:1107  | Downloaded:174
    +HTML| PDF
  • Topic: Circulating Tumor Cells: Diagnostics and Clinical Applications|Open Access

    The significance and clinical utility of the detection of primary malignant circulating prostate cells: a review of the evidence

    Nigel P. Murray
    Primary malignant circulating prostate cells (CPCs) are those detected in blood before definitive treatment for prostate cancer. CPCs can be detected in men with benign prostate disease; however, some methods to distinguish between benign and malignant prostate cells have to be validated. This study presents a review of the subject, including theoretical considerations for the selection of markers to detect them, the different methods used, and the utility of their detection in identifying men with prostate cancer and as a prognostic factor. Read more
    J Cancer Metastasis Treat 2016;2:453-62. | doi:10.20517/2394-4722.2016.55
    Published on: 16 Dec 2016  | Viewed:1096  | Downloaded:126
    +HTML| PDF
  • Review|Open Access

    Changing paradigm in treatment of lung cancer

    Sundaram Viswanath , Abhishek Pathak , Amul Kapoor , Anvesh Rathore , Bhupendra Nath Kapur
    Lung cancer is one of the most common and deadliest forms of cancer. It accounts for 13% of all new cancer cases and 19% of cancer-related deaths. In India, lung cancer constitutes 6.9% of all new cancer cases and 9.3% of all cancer cases. There has also been a dramatic rise worldwide in both the absolute and relative frequencies of lung cancer occurrence. In 1953 it became the most common cause of cancer mortality in men. By 1985, it became the leading cause of cancer deaths in women, causing almost twice as many deaths as breast cancer. The demographic profile of lung cancer has changed... Read more
    J Cancer Metastasis Treat 2016;2:214-9. | doi:10.20517/2394-4722.2015.88
    Published on: 15 Jun 2016  | Viewed:1076  | Downloaded:236
    +HTML| PDF
  • Topic: How does the prostate cancer microenvironment affect the metastatic process and/or treatment outcome?|Open Access

    Getting better at treating prostate cancer: what clinicians should want from scientists

    Malcolm Mason
    If the treatment landscape for prostate cancer is to be transformed, clinicians and scientists must work together ever more closely. Prostate cancer defeats physicians when patients are not accurately stratified according to patients’ risk of dying of disease, when the effects of tumor heterogeneity are insufficiently understood, and when attempts at therapy by clinicians spur further disease evolution and the emergence of new resistance mechanisms. At the same time, clinicians’ over-treat men who in reality do not need it, and some of those men needlessly suffer long term side effects as a... Read more
    J Cancer Metastasis Treat 2017;3:271-7. | doi:10.20517/2394-4722.2017.51
    Published on: 17 Nov 2017  | Viewed:1071  | Downloaded:67
    +HTML| PDF
  • Topic: How does the prostate cancer microenvironment affect the metastatic process and/or treatment outcome?|Open Access

    Getting closer to prostate cancer in patients - what scientists should want from clinicians

    Norman J. Maitland
    For scientists pursuing drug development for prostate cancer, it is critical that an appropriate ex vivo or in vitro model system is available for study. Cancer research has generally consisted of: (1) finding the means to arrest fast growing cancer cells; or (2) (as a compromise) to slow down the excessive rate of cell growth; or in the best case (3) to kill the cancer cells whilst sparing the surrounding normal tissues. As the knowledge of the biological nature of the cancer cell improves, it has become increasingly apparent that such a simplistic attitude to cancer therapy development or... Read more
    J Cancer Metastasis Treat 2017;3:262-70. | doi:10.20517/2394-4722.2017.23
    Published on: 17 Nov 2017  | Viewed:1056  | Downloaded:70
    +HTML| PDF
  • Topic: Neuroendocrine Tumors|Open Access

    Double tracer PET/CT: what is it and what does it mean?

    Mattia Pellicciari , Silvia Ortolani , Elisabetta Grego , Giampaolo Tortora , Sara Cingarlini
    68Ga-DOTA-peptide PET/CT is a recommended imaging modality in the workup of neuroendocrine neoplasms (NENs), which shows high diagnostic sensitivity and is a strong predictor of successful somatostatin receptor directed treatments. Although not routinely recommended, reliable evidences show that 18F-FDG PET/CT can provide complementary information in this setting with the ability to discriminate slow-proliferating tumors from aggressive, rapidly-proliferating tumors. Further, it has been proposed as an independent prognostic factor for the prediction of either overall survival or... Read more
    J Cancer Metastasis Treat 2016;2:321-8. | doi:10.20517/2394-4722.2016.45
    Published on: 31 Aug 2016  | Viewed:1019  | Downloaded:144
    +HTML| PDF
  • Original Article|Open Access

    Percutaneous, computed tomography guided neurolysis using continuous radiofrequency for pain reduction in oncologic patients

    Periklis Zavridis , Maria Tsitskari , Argyro Mazioti , Dimitrios Filippiadis
    Aim: This study evaluates the efficacy and safety of percutaneous computed tomography (CT)-guided neurolysis using continuous radiofrequency for pain reduction in oncologic patients. Methods: Over the course of 16 months, 22 patients underwent radiofrequency neurolysis as palliative therapy for pain reduction in celiac and splachnic plexus (n = 9), thoracic (n = 1), lumbar (n = 2) and superior hypogastric plexus (n = 5), as well as stellate ganglion (n = 5). Pain levels before treatment, one week after treatment, and at the last follow-up (average follow-up 6 months) were compared by means... Read more
    J Cancer Metastasis Treat 2017;3:60-4. | doi:10.20517/2394-4722.2017.04
    Published on: 27 Mar 2017  | Viewed:1008  | Downloaded:75
    +HTML| PDF
  • Case Report|Open Access

    Report of primary leiomyosarcoma of renal pelvis and literature review

    Abhidha Malik , Ritesh Kumar , Abhishek Shankar , Sunil Chumber , Sameer Bakhshi , Seema Kaushal , Bala Thirunavukkarasu
    Primary sarcomas of kidney are exceptionally rare tumors, accounting for only 1-2% of all malignant tumors of kidney. Leiomyosarcoma (LMS) is the most common histological subtype among all renal sarcomas. The authors describe here a case of primary leiomyosarcoma of renal pelvis in a 50-year-old lady, presenting with flank pain. Based on triple phase cardio-electroencephalographic covariance tracing abdomen, presumptive diagnosis of renal cell carcinoma/renal sarcoma/neurogenic tumor was made and patient underwent radical nephrectomy. Microscopy reflected spindle cell tumor which showed... Read more
    J Cancer Metastasis Treat 2017;3:111-5. | doi:10.20517/2394-4722.2017.12
    Published on: 30 Jun 2017  | Viewed:1002  | Downloaded:73
    +HTML| PDF
  • Original Article|Open Access

    Gastric cancer treated with pressurized intraperitoneal aerosol chemotherapy: revising an option for peritoneal carcinomatosis

    Filipa Macedo , Kátia Ladeira , Adhemar Longatto-Filho , Sandra F. Martins
    Aim: Gastric cancer is the cancer with the highest rate of peritoneal metastization and this type of spread is associated with a higher death rate compared to distant organ metastasis. The systemic chemotherapy has a minimal effect in peritoneal metastasis so new types of treatment have emerged. The authors revised the main studies done in pressurized intraperitoneal aerosol chemotherapy (PIPAC) and presented the main conclusions. Methods: A PubMed search was conducted focusing on PIPAC in gastric cancer. The MeSH database was searched with the terms: “Gastric cancer [MeSH] and... Read more
    This article belongs to the Special Issue Reviews of Gastric Cancer Metastasis and Treatment
    J Cancer Metastasis Treat 2018;4:8. | doi:10.20517/2394-4722.2017.72
    Published on: 9 Feb 2018  | Viewed:977  | Downloaded:77
    +HTML| PDF
  • Topic: Cancer Stem Cells: Impact on Treatment|Open Access

    The quintessential quiescence of cancer stem cells: a struggle towards better treatment

    Anuradha Vaidya
    J Cancer Metastasis Treat 2016;2:243-4. | doi:10.20517/2394-4722.2016.10
    Published on: 8 Jul 2016  | Viewed:935  | Downloaded:166
    +HTML| PDF
  • Topic: Cancer Immunotherapy|Open Access

    Cell-mediated immunotherapy for hepatocellular carcinoma

    Wei-Chen Lee
    Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Most of the time, these tumors are diagnosed at late stages. Because no effective treatments exist for patients with advanced stage HCC, there is an urgent need for novel, effective treatments. Cancer cells originate as a consequence of abnormal expression of oncogenes or loss of tumor suppressor genes. Often, neoplastic transformation results in a hyper-mutated cellular genome, which in turn produces neo-antigens from mutated genes. These tumor-specific or tumor-associated antigens can be recognized by... Read more
    J Cancer Metastasis Treat 2017;3:244-9. | doi:10.20517/2394-4722.2017.48
    Published on: 31 Oct 2017  | Viewed:865  | Downloaded:105
    +HTML| PDF
  • Commentary|Open Access

    Immunotherapy of cancer is a part of biotherapy

    Shuen-Kuei Liao , Robert K. Oldham
    This article belongs to the Special Issue Cancer Immunotherapy
    J Cancer Metastasis Treat 2018;4:3. | doi:10.20517/2394-4722.2017.63
    Published on: 22 Jan 2018  | Viewed:838  | Downloaded:118
    +HTML| PDF
  • Review|Open Access

    Microenvironment in the pathogenesis of gastric cancer metastasis

    Hiroshi Sawayama , Takatsugu Ishimoto , Hideo Baba
    Tumor tissues contain cancer cells, other cellular and non-cellular components. Tumor microenvironments consist of cancer cells and various types of stromal cells, cancer associated fibroblasts, bone marrow-derived cells, endothelial cells, and hematopoietic cells, mainly tumor-associated macrophages and tumor-infiltrating lymphocytes. Increasing recent evidence has demonstrated that alteration of tumor microenvironments is deeply implicated in tumor progression and metastasis in gastric cancer (GC) patients. Recent investigations have provided insights into the molecular mechanisms of the... Read more
    This article belongs to the Special Issue Reviews of Gastric Cancer Metastasis and Treatment
    J Cancer Metastasis Treat 2018;4:10. | doi:10.20517/2394-4722.2017.79
    Published on: 28 Feb 2018  | Viewed:827  | Downloaded:93
    +HTML| PDF
  • Review|Open Access

    Significance of peritoneal lavage cytology based on genetic signatures in gastric cancer

    Tasuku Matsuoka , Masakazu Yashiro
    Peritoneal metastasis is the most common pattern of recurrence and the most frequent cause of death after surgery in patients with gastric cancer. Peritoneal free cancer cells disseminated from the primary lesion site have been considered the main cause of peritoneal metastasis. Peritoneal lavage cytological examination (PLC) has been shown to be an independent predictor of gastric cancer relapse after curative resection and poor overall survival. However, the conventional cytological examinations have high rates of false-positive and false-negative findings. To improve the sensitivity,... Read more
    This article belongs to the Special Issue Reviews of Gastric Cancer Metastasis and Treatment
    J Cancer Metastasis Treat 2018;4:6. | doi:10.20517/2394-4722.2017.85
    Published on: 9 Feb 2018  | Viewed:780  | Downloaded:60
    +HTML| PDF
  • Original Article|Open Access

    Health-related quality of life and its correlates among rectal cancer survivors, Northwest of Iran

    Nayyereh Aminisani , Mehdi Fatemi , Parvin Sarbakhsh , Alireza Nikanfar , Amirtaher Eftekharsadat , Esmat Jafari
    Aim: The objective of this study was to examine the health-related quality of life (HRQOL), and its correlates among rectal cancer survivors in northwest of Iran. Methods: This cross-sectional study was conducted in northwest of Iran. Rectal cancer survivors were selected from teaching hospitals. HRQOL was estimated using the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire C30. Information about socio-demographic, lifestyle and clinical features of disease was obtained by trained interviewers. Results: A total of 96 patients were included in this... Read more
    J Cancer Metastasis Treat 2017;3:209-16. | doi:10.20517/2394-4722.2017.47
    Published on: 29 Sep 2017  | Viewed:768  | Downloaded:70
    +HTML| PDF
  • Review|Open Access

    Therapeutic targets against gastric cancer stem cells interacting with tumor microenvironment

    Tomoyuki Uchihara , Takatsugu Ishimoto , Atsuko Yonemura , Hideo Baba
    Gastric cancer (GC) is a major cause of cancer-related deaths worldwide. The existence of cancer stem cells (CSCs) is known to be the main reason for resistance to anticancer agents as well as for the development of distant metastases. Although CSCs themselves harbor self-renewal and differentiation abilities, the tumor microenvironment that surrounds CSCs provides secreted factors and supports angiogenesis and is thus responsible for the maintenance of their CSC properties. The current review provides information regarding the impact of the tumor microenvironment on gastric CSCs, which... Read more
    This article belongs to the Special Issue Reviews of Gastric Cancer Metastasis and Treatment
    J Cancer Metastasis Treat 2018;4:9. | doi:10.20517/2394-4722.2017.81
    Published on: 26 Feb 2018  | Viewed:764  | Downloaded:85
    +HTML| PDF
  • Commentary|Open Access

    Adenosine A2B receptor: novel anti-cancer therapeutic implications

    Silvia Paola Corona , Navid Sobhani , Daniele Generali
    J Cancer Metastasis Treat 2017;3:206-8. | doi:10.20517/2394-4722.2017.50
    Published on: 27 Sep 2017  | Viewed:764  | Downloaded:102
    +HTML| PDF
  • Commentary|Open Access

    Targeting adenosine receptor 2B in triple negative breast cancer

    Carola A. Neumann , Kevin Levine , Steffi Oesterreich
    J Cancer Metastasis Treat 2018;4:13. | doi:10.20517/2394-4722.2017.60
    Published on: 15 Mar 2018  | Viewed:708  | Downloaded:58
    +HTML| PDF
  • Review|Open Access

    The magnitude of benefit from adding taxanes to anthracyclines in the adjuvant settings of breast cancer: discussion of large trials and meta-analyses

    Osama H. Elzaafarany , Atlal Abusanad
    The taxanes family of chemotherapy, which includes paclitaxel and docetaxel, has been incorporated in the adjuvant breast cancer treatments since 1990s. Sequential and concurrent use of taxanes was investigated with anthracyclines in many adjuvant early breast cancer randomized clinical trials. Results from taxanes trials showed inconsistent benefits. However, several meta-analyses showed significant survival benefit of adding taxanes. In this review article, data were collected and summarized from eleven large randomized trials and three meta-analyses to show and discuss the magnitude of... Read more
    J Cancer Metastasis Treat 2018;4:14. | doi:10.20517/2394-4722.2017.55
    Published on: 15 Mar 2018  | Viewed:598  | Downloaded:44
    +HTML| PDF
  • Topic: Cancer Immunotherapy|Open Access

    Introduction to the Special Issue on Cancer Immunotherapy

    Shuen-Kuei Liao
    J Cancer Metastasis Treat 2017;3:217. | doi:10.20517/2394-4722.2017.21
    Published on: 31 Oct 2017  | Viewed:535  | Downloaded:91
    +HTML| PDF
  • Original Article|Open Access

    Nodal involvement and p16-staining in upper alveolar ridge and hard palate cancer

    Edgar Salas , Pedro Sanchez , Juan Postigo , Carlos A. Castaneda , Miluska Castillo , Valeria Villegas , Luis Cano , Sandro Casavilca , Luis A. Bernabe , Carolina Belmar , Maria R. Villa-Robles , Raul Mantilla , Henry Guerra
    Aim: Upper alveolar ridge and hard palate squamous cancer is an infrequent malignancy. We evaluated factors associated with neck involvement and with p16-staining. Methods: Head and neck squamous-cell carcinoma (SCC) patients who went to Head and Neck Department between 1997 and 2011 were screened, and 73 resected upper alveolar ridge and 5 hard palate SCC were selected. Tumors with available tissue were stained with p16 immunohistochemistry. Results: Median age was 64.4 years, 55.1% were female, and 73.1% were in clinical stage IV. Neck dissections were performed in 24 and pathologically... Read more
    J Cancer Metastasis Treat 2018;4:15. | doi:10.20517/2394-4722.2017.66
    Published on: 28 Mar 2018  | Viewed:519  | Downloaded:30
    +HTML| PDF
  • Review|Open Access

    The role of long noncoding RNAs in cancer metastasis

    Christine Parsons , Alexis M. Tayoun , Benjamin D. Benado , Gabriel Ragusa , Rose F. Dorvil , Elizabeth A. Rourke , Kaitlyn O’ Connor , Irene G. Reed , Angela Alexander , Lian Willetts , Maryam Habibian , Brian D. Adams
    Signaling pathways are tightly controlled systems that regulate the appropriate timing of gene expression required for the differentiation of cells down a particular lineage essential for proper tissue development. Proliferation, apoptosis and metabolic pathways are just a few examples of the signaling pathways that require fine-tuning, so as to control the proper development of a particular tissue type or organ system. An estimated 70% of the genome is actively transcribed, only 2% of which codes for known protein-coding genes. Long noncoding RNAs (lncRNAs) in particular, are a large and... Read more
    J Cancer Metastasis Treat 2018;4:19. | doi:10.20517/2394-4722.2018.11
    Published on: 28 Apr 2018  | Viewed:485  | Downloaded:54
    +HTML| PDF
  • Meta-Analysis|Open Access

    The potential prognostic and predictive roles of programmed cell death protein 1 expressed by tumor-infiltrating lymphocytes in solid tumors: a meta-analysis

    Dong-Yun Zhang , Rong-Zhi Liu , Jian-Wei Ku , Yu-Hong Ma , Ying-Jie Yi
    Aim: Several previous studies have evaluated the potential role of programmed cell death protein 1 (PD-1) expressed by tumor-infiltrating lymphocytes (TILs) in various solid tumors and performed its prognosis role in patients’ survival with inconsistent results. This study aims to further systematically evaluate the association of PD-1 by TILs with clinicopathological parameters and clinical outcomes in solid tumor patients. Methods: A comprehensive search was conducted in PubMed, Embase, Web of Science, CNKI and Wanfang databases for relevant studies. The potential prognostic and... Read more
    J Cancer Metastasis Treat 2018;4:16. | doi:10.20517/2394-4722.2018.01
    Published on: 12 Apr 2018  | Viewed:381  | Downloaded:60
    +HTML| PDF
  • Review|Open Access

    Recent trend in gastric cancer treatment in the USA

    Kazuto Harada , Hideo Baba , Jaffer A. Ajani
    Gastric adenocarcinoma (GAC) is estimated as the fifteenth most common cancer in the USA. Incidence rate has been gradually decreasing, but prognosis remains dismal. For patients with locally advanced GAC (stage > T1B and < T4B), multimodality therapies, such as surgery, chemotherapy, and radiation therapy, are needed. Perioperative chemotherapy or postoperative chemoradiation/chemotherapy is recommended. For metastatic GAC patients, combination of two cytotoxics (platinum compound and fluoropyrimidine) has become a common place in the USA, and when HER2 is positive, trastuzumab is... Read more
    This article belongs to the Special Issue Reviews of Gastric Cancer Metastasis and Treatment
    J Cancer Metastasis Treat 2018;4:18. | doi:10.20517/2394-4722.2017.74
    Published on: 26 Apr 2018  | Viewed:347  | Downloaded:41
    +HTML| PDF
  • Original Article|Open Access

    The combined analysis of solid and liquid biopsies provides additional clinical information to improve patient care

    Ana Finzel , Helen Sadik , Gregori Ghitti , Jean-François Laes
    Aim: To investigate if the genetic information provided by sequencing of both solid and liquid biopsies can shed light on tumor heterogeneity, and to understand the clinical usefulness of adding blood profiling to standard tissue analysis in cancer care. Methods: Data from 351 patients with stage IV solid tumors for whom molecular profiling of their solid and liquid biopsies was available were studied, with a focus on the discrepant molecular information found between tissue and blood samples. Results: In 86% of patients, solid and liquid biopsies provided different molecular information.... Read more
    J Cancer Metastasis Treat 2018;4:21. | doi:10.20517/2394-4722.2018.10
    Published on: 8 May 2018  | Viewed:337  | Downloaded:27
    +HTML| PDF
  • Review|Open Access

    Prostate cancer cells at a therapeutic gunpoint of the autophagy process

    Fabio Gabriele , Carolina Martinelli , Sergio Comincini
    In a normal prostate, the process of controling cell death is essential to maintain tissue homeostasis and its inhibition may lead to the development of cancer. Androgen receptor signaling plays pivotal roles in the prostate development and homeostasis as well as in the progression of prostate cancer. The main treatment for prostate cancer is a combination of androgen deprivation therapy (ADT) using anti-androgens and docetaxil administration. However, ADT eventually fails due to a pathological unbalance of cell death processes, in particular apoptosis and autophagy. As a result prostate... Read more
    This article belongs to the Special Issue Autophagy and Cancer: current biology and drug development
    J Cancer Metastasis Treat 2018;4:17. | doi:10.20517/2394-4722.2018.06
    Published on: 19 Apr 2018  | Viewed:296  | Downloaded:25
    +HTML| PDF
  • Review|Open Access

    Conversion surgery for stage IV gastric cancer

    Satoshi Ida , Masayuki Watanabe
    Gastric cancer with distant metastases, such as para-aortic lymph node metastases, hepatic metastases, and peritoneal dissemination, is classified as stage IV. In this situation, cancer cells have formed micrometastases throughout the body; therefore, according to the algorithm of the Japanese guidelines, stage IV cancer is outside the indication for curative resection. Recent advances in some chemical agents have been remarkable, and some patients have survived for long periods even with stage IV gastric cancer. Thus, even in patients with stage IV gastric cancer, there is a possibility... Read more
    This article belongs to the Special Issue Reviews of Gastric Cancer Metastasis and Treatment
    J Cancer Metastasis Treat 2018;4:22. | doi:10.20517/2394-4722.2017.75
    Published on: 16 May 2018  | Viewed:105  | Downloaded:6
    +HTML| PDF
  • Review|Open Access

    Treatment strategy for metastatic gastric cancer in Japan

    Kojiro Eto , Satoshi Ida , Masayuki Watanabe , Hideo Baba
    Despite recent progress in diagnostic imaging, gastric cancer (GC) is occasionally found at an advanced stage with distant metastasis. As metastatic GC is difficult to cure, the treatment strategy should be considered individually based on the physical and socioeconomic status of patients as well as on the GC symptoms. The first choice of treatment for metastatic GC is chemotherapy, and several chemotherapeutic regimens for metastatic or recurrent GC have been developed through randomized controlled trials. Ongoing clinical trials will provide novel therapeutic options for patients with... Read more
    This article belongs to the Special Issue Reviews of Gastric Cancer Metastasis and Treatment
    J Cancer Metastasis Treat 2018;4:23. | doi:10.20517/2394-4722.2017.73
    Published on: 16 May 2018  | Viewed:78  | Downloaded:2
    +HTML| PDF
  • Letter|Open Access

    Hypoxia in prostate cancer

    Peter Vaupel
    J Cancer Metastasis Treat 2018;4:20. | doi:10.20517/2394-4722.2018.30
    Published on: 7 May 2018  | Viewed:76  | Downloaded:6
    +HTML| PDF
  • Review|Open Access

    Management of metastatic esophagogastric junction adenocarcinoma

    Tasuku Toihata , Yu Imamura , Masayuki Watanabe , Hideo Baba
    The prognosis of metastatic disease of esophagogastric junction adenocarcinoma remains poor, despite using a variety of regimens using cytotoxic agents. Recent understanding of molecular characteristic and tumor microenvironment of this cancer is currently instigating new therapeutic options. In this review, we summarized previous evidences of cytotoxic agents widely used worldwide, and updated recent developments of molecular targeted drugs, and immune checkpoint inhibitors. Read more
    This article belongs to the Special Issue Reviews of Gastric Cancer Metastasis and Treatment
    J Cancer Metastasis Treat 2018;4:24. | doi:10.20517/2394-4722.2017.82
    Published on: 17 May 2018  | Viewed:54  | Downloaded:2
    +HTML| PDF
Journal of Cancer Metastasis and Treatment Print ISSN: 2394-4722; Online ISSN: 2454-2857
Partners
Copyright © 2018 OAE Publishing Inc. All Rights Reserved.